CDH1 and neoplasm: In accordance, TGVs located in most- or standard-actionable genes accounted for most germline relevant variants (30/44), many of which have a GCR ≥50% in any tumor and age context (63%; 19/30): ATM, BRCA1, BRCA2, CHEK2, FLCN, MLH1, MSH2, and RET. Clinical judgment due to related phenotypes (AXIN2, CDH1, MEN1, MUTYH, NF1, RNF43, and VHL), was an important factor for recommending GGT testing, regardless of VAF or GCR.